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Abstract
Background: Stem cells/progenitors are central to the development of cell therapy approaches for vascular ischemic
diseases. The crucial step in rescuing tissues from ischemia is improvement of vascularization that can be achieved by
promoting neovascularization. Endothelial progenitor cells (EPCs) are the best candidates for developing such an approach
due to their ability to self-renew, circulate and differentiate into mature endothelial cells (ECs). Studies showed that
intravenously administered progenitors isolated from bone marrow, peripheral or cord blood home to ischemic sites.
However, the successful clinical application of such transplantation therapy is limited by low quantities of EPCs that can be
generated from patients. Hence, the ability to amplify the numbers of autologous EPCs by long term in vitro expansion
while preserving their angiogenic potential is critically important for developing EPC based therapies. Therefore, the
objective of this study was to evaluate the capacity of cord blood (CB)-derived AC133+ cells to differentiate, in vitro, towards
functional, mature endothelial cells (ECs) after long term in vitro expansion.
Methodology: We systematically characterized the properties of CB AC133+ cells over the 30 days of in vitro expansion.
During 30 days of culturing, CB AC133+ cells exhibited significant growth potential that was manifested as 148-fold increase
in cell numbers. Flow cytometry and immunocytochemistry demonstrated that CB AC133+ cells’ expression of endothelial
progenitor markers was not affected by long term in vitro culturing. After culturing under EC differentiation conditions, cells
exhibited high expression of mature ECs markers, such as CD31, VEGFR-2 and von Willebrand factor, as well as the
morphological changes indicative of differentiation towards mature ECs. In addition, throughout the 30 day culture cells
preserved their functional capacity that was demonstrated by high uptake of DiI fluorescently conjugated-acetylated-low
density lipoprotein (DiI-Ac-LDL), in vitro and in vivo migration towards chemotactic stimuli and in vitro tube formation.
Conclusions: These studies demonstrate that primary CB AC133+ culture contained mainly EPCs and that long term in vitro
conditions facilitated the maintenance of these cells in the state of commitment towards endothelial lineage.
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Introduction
Over the last few decades stem cells/progenitors became focus of
the development of cell therapy approaches for various diseases,
including vascular ischemic diseases. The crucial step in rescuing
tissues from ischemia is improvement of vascularization that can be
achieved by promoting neovascularization or growth of new blood
vessels. Formation of blood vessels involves two processes:
vasculogenesis and angiogenesis [1]. Vasculogenesis was believed
to be restricted to embryonic development and is achieved by in situ
differentiation of the primitive progenitors, i.e. angioblasts into
mature endothelial cells (ECs) and their organization into a primary
capillary network [2,3]. In contrast, angiogenesis occurs both during
embryonic development and postnatal life and is carried out by
endothelial migration and sprouting from preexisting vessels [4,5].
For a long time it was considered that postnatal blood vessel
formation is restricted to angiogenesis only. Since numerous previous
studies demonstrated the existence of circulating ECs in peripheral
blood in various vascular diseases [6,7,8,9,10] the question was asked
whether these cells (or their precursors) play a role in the postnatal
vascular growth. The ground breaking evidence implicating the
possibility that endothelial stem or precursor cells may contribute to
the formation of new blood vessels in adults, by vasculogenesis, came
from the work by Asahara et al. [11]. They demonstrated the
presence of CD34+ endothelial progenitors in human peripheral
blood, capable of incorporating into the sites of active angiogenesis.
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postnatal vascularization, and endothelial progenitor cells (EPCs) in
particular, have been suggested to take part in these processes by
homing to the sites of neovascularization and by differentiating into
ECs. Therefore, EPCs seem like excellent candidates for developing
therapeutic approaches for human vascular diseases.
In spite of the growing evidence on therapeutic potential of
EPCs, definition, phenotypic and functional characterization as
well as angiogenic role of the putative EPC still remains
controversial. EPCs are considered as bone marrow-derived cells
that have the capacity to proliferate, circulate and differentiate
into mature ECs. However, many groups used adult peripheral
blood and placental cord blood as a source for endothelial
progenitors [12,13,14], with a various degree of success in
demonstrating angiogenic properties of these differently isolated
starting population. In addition, EPCs propagated under different
culture conditions, such as suspension vs. adherent culture, and in
the presence of different cytokine combinations, exhibited
significant differences with regard to phenotypes, function and
very often, proliferative potential as well [14,15]. Earlier studies
defined EPCs as the cells co-expressing hematopoietic stem cell
(HSC) marker CD34 and EC marker, vascular endothelial
growth factor receptor 2 (VEGFR2) [16]. However, subsequent
studies demonstrated that some mature ECs also co-express
CD34 and VEGFR2. In addition, CD34 was shown not to be an
exclusive marker for hematopoietic cells and novel AC133
glycoprotein was accepted as a more suitable marker for
immature progenitor cells [14,17] that is expressed on HSC but
not on mature ECs [18,19]. A subset of circulating CD34+ cells
that express both, VEGFR-2 and AC133, was also suggested to
represent a functional EPC population that plays a role in
postnatal angiogenesis or vasculogenesis [17]. It has been
hypothesized that CD133+/CD34+/VEGFR2+ cells represent
an immature, highly proliferative EPC population that gives rise
to CD133-/CD34+/VEGFR2+ cells that are more mature and
limited in their proliferative capacity [20]. Through the process of
differentiation into mature ECs, EPCs down-regulate the
expression of CD34 and AC133 [19,21] and continuous culturing
increases the expression of mature EC markers [22]. However,
the overlap of phenotypical and functional properties among
EPCs, HSCs and ECs remains the source of controversy and it is
still not clear what the ‘‘real’’ identity of EPCs is and whether
their angiogenic potential is contingent on differentiation/
maturation status. Nevertheless, the majority of studies using
progenitors from bone marrow, peripheral or cord blood
demonstrated the ability of these cells to self-renew, circulate
and differentiate and these properties are central to the
development of EPC-based therapies. However, the successful
clinical application of such transplantation approach is limited by
low quantities of EPCs that can be generated form a patient.
Hence, the ability to in vitro amplify the numbers of autologous
EPCs while preserving their angiogenic potential, is critically
important for developing EPC based therapies for ischemic
vascular diseases.
The aim of this study was to establish the optimal conditions for
the in vitro expansion of cord blood (CB) derived AC133+
progenitor cells that would enable long term expansion of cell
numbers without affecting angiogenic potential of the expanded
population. We analyzed the phenotypical and functional
characteristics of CB AC133+ cells that were expanded in vitro in
the presence of SCF, TPO and Flt3 for up to 30 days. Our results
indicated that long term in vitro culturing did not impede the CB
AC133+ potential to give rise to the population exhibiting
endothelial cell type characteristics.
Materials and Methods
Ethics Statement
The use of human cord blood in this study was approved by a
Henry Ford Health System Institutional Review Board (IRB). Written
informed consent was obtained and the consent process was
maintained under IRB-approved security protocol using an IRB-
approved consent form and the process of consent. Animal
experiments were performed according to the protocol approved by
our animal care and user committee at Henry Ford Health System.
Isolation and In Vitro Culture of AC133+ EPC
Progenitor cells positive for CD133+ marker (AC133+)w e r e
isolated from the cord blood obtained from volunteers entered in
Institutional Review Board (IRB) approved protocols. The cord
blood mononuclear cell population was generated by Ficoll gradient
centrifugation and was enriched for AC133+ cells by immunomag-
netic positive selection using the MidiMACS system (Miltenyi
Biotec, Auburn CA) according to the manufacturer’s protocol.
Freshly isolated AC133+ cells were suspended in Stemline II media
(Sigma, St. Louis, MO) supplemented with 40 ng/ml of stem cell
factor (SCF), 40 ng/ml of FLT3 and 10 ng/ml of thrombopoietin
(TPO) (all from CellGenix, IL). Cells were maintained under these
conditions as a suspension culture for 30 days with the cell
concentration kept between 5610
5–1610
6 cells/ml. Throughout
the 30 days of long term expansion, cells were cultured in BD
Falcon
TM 6-well cell culture dishes (BD Biosciences) and monitored
daily by inverted phase contrast microscopy. At splitting, the
number of live cells was determined by Trypan blue exclusion assay
and the data was used to generate growth curve. Upon determining
the cell count, cells were split by adding freshly prepared media to
adjust the concentration to 5610
5 cells/ml.
Human Dermal Microvascular Endothelial Cells
(HDMVEC)
Human dermal microvascular endothelial cells (HDMVEC)
were purchased from Cambrex (East Rutherford, NJ). Cells were
grown in microvessel growth supplement media 131 (Cambrex
East Rutherford, NJ) according to the manufacturer’s recommen-
dations and maintained at 37uC in a humidified incubator
containing 5% CO2.
In Vitro Differentiation of AC 133+ EPCs
Differentiation potential of primary long term AC133+EPC
culture was assessed at days 5–6, 10–15 and 25–30 of in vitro
expansion. Cells were suspended in Stemline II media supplemented
with 2% FBS and 2 ng/ml of Vascular Endothelial Growth Factor
(VEGF) and plated in chamber slides coated with fibronectin at a
concentration of 2610
5/ml. Cells were allowed to differentiate for 2
weeks. Every 2–3 days, old media was replenished with fresh media,
in each chamber, and cells were monitored by inverted phase
contrast microscopy to assess the morphological changes associated
with differentiation. After 2 weeks of differentiation cell were
analyzed by flow cytometry and immunocytochemistry for the
expression of EPC differentiation markers.
Flow Cytometry
Cells expanded as suspension culture under the growth
conditions or cells grown under the differentiation conditions
were harvested, washed in ice cold 1x PBS and incubated for
30 min on ice, in dark, with the respective fluorescently labeled
antibodies. Fluorescence activated flow cytometry was performed
with LSR II (Becton Dickinson) flow cytometer and a minimum of
Cord Blood AC133+ Cells
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the analysis, were gated based on forward angle light scatter (FSC)
and side angle light scatter (SSC) characteristics and further
analyzed using the Cell Quest Pro software (Becton Dickinson).
Specific antibodies that were used in flow cytometric experiments
to analyze the expression of cell surface markers were: mouse anti-
human CD133 IgG1 (Miltenyi Biotec, Auburn CA), mouse anti-
human CD34 IgG1 (BioLegend), mouse anti-human CD45 IgG1
(BioLegend), mouse anti-human CD117 IgG1 (BioLegend), mouse
anti-human CD14 IgG1 (BioLegend), mouse anti-human CD20
IgG2b (BioLegend), mouse anti-human CD3 IgG2b (BioLegend),
mouse anti-human CD29 IgG1 (BioLegend), mouse anti-human
CD31 IgG1 (BioLegend), mouse anti-human CD54 IgG2a
(BioLegend), mouse anti-human KDR (VEGFR2) IgG1 (R&D
Systems), mouse anti-human VE-Cadherin IgG2b (R&D Systems),
mouse anti-human CD106 IgG1 (BioLegend), mouse anti-human
CD62E IgG2a (BioLegend), mouse anti-human CD184 IgG2a
(BioLegend), mouse anti-human CD195 IgG2a (BioLegend),
mouse anti-human CD105 IgG2a (BioLegend), mouse anti-human
CD150 IgG1, mouse anti-human CD140 A and B IgG1
(BioLegend). All the antibodies were used in the concentrations
suggested by the suppliers.
Immunocytochemistry
Differentiated AC133+ EPCs were analyzed by immunocyto-
chemistry for the expression of endothelial cell specific markers.
The following specific antibodies were used: mouse anti-human anti
CD31 (DakoCytomation), rabbit anti-human anti CD309
(VEGFR2 or KDR) (Thermo Scientifics) and rabbit anti-human
anti von Willebrand Factor (vWF)(DakoCytomation). Positive
staining was detected using Texas Red or FITC conjugated
secondary antibodies (Jackson ImmunoResearch, Inc). Negative
control samples included cells treated with secondary antibodies
only. All the antibodies were used in the concentrations suggested
by the suppliers. To visualize nuclei, cells were counterstained with
DAPI nuclear stain. Cells were analyzed by fluorescent microscopy.
EPCs Migration in Response to SDF-1 and Rantes
Chemotactic assay was performed using QCM
TM Chemotaxis
3 mm pores 96-well Cell Migration Assay kit (Chemicon)
according to the supplier’s experimental protocol. In brief,
1610
5 cells were suspended in 100 ml of serum free media and
placed in the upper compartment of transwell chamber. Lower
compartments were filled with 150 ml of serum free media, with or
without 50 ng/ml of SDF-1 (CXCL12) or 50 ng/ml of Rantes
(CCL5). Each sample was assayed in triplicates and after
incubation of 4 h at 37uC, cell migration was detected as
fluorescence that was read using 520 nm filter set. EPCs migration
in response to Rantes and SDF-1 was compared to the migration
observed in control EPCs incubated without chemoatractant and
EPCs incubated with 10% FBS (positive control).
Endothelial Tube Formation in Matrigel
Ability of CB AC133+ cells to differentiate and organize into
capillary-like structures in the presence of basement membrane
matrix was analyzed using BioCoat Matrigel 35 mm Cellware (BD
Bioscience) according to the manufacturer’s suggestions. To assess
the possible paracrine proangiogenic effect of CB AC133+ cells on
microvascular endothelial cells, HDMVEC were cultured on
BioCoat Matrigel together with CB AC133+ cells or in the presence
of CB AC133+ cells’ conditioned media (supernatant collected from
CB AC133+ cell culture). In brief, 2610
4 of EPCs were plated onto
the rehydrated Matrigel in the media free of serum and growth
factors and incubated for 24 hours at 37uC, 5% CO2. Tube
formation was monitored by microscope. For the co-culture
experiments, CB AC133+ cells were labeled with red fluorescent
dye DiI (Molecular Probes) while HDMVEC were labeled with
green fluorescent reagent Calcein (Molecular Probes). Labeling
procedures were done following the manufacturers’ protocols. CB
AC133+ cells (2610
4)w e r em i x e dw i t hH D M V E C( 1 610
5). In one
set of wells HDMVEC (1610
5) were incubated in the presence of
CB AC133+ cells’ supernatants only. Tube formation was assessed
according to the manufacture’s recommendations.
Incorporation of DiI-Ac-LDL
At days 5–6, 10–15 and 25–30 of in vitro primary culture cells
were differentiated for 2 weeks as described. Upon differentiation,
cells were incubated in the presence of 10 mg/ml of acetylated low
density lipoprotein, labeled with 1,19-dioctadecyl – 3,3,39,39-
tetramethyl-indocarbocyanine perchlorate, DiI-Ac-LDL (Biomed-
ical Technologies, Inc). After 4 h of incubation at 37uC, 5%CO2,
cells were washed with probe free-media, fixed in 3% parafor-
maldehyde and analyzed by fluorescent microscopy using
rhodamine excitation/emission filters.
Preparation of Ferumoxides-Protamine Sulfate (FePro)
Complex and Labeling of CB AC133+ Cells
For the purpose of labeling, CB AC133+ cells were suspended at
the concentration of 4610
6 cell/ml in serum free RPMI and plated
in 24-well plate cell culture dish, 0.5 ml per well. The labeling
procedure was performed according to our previously published
method [23]. In brief, commercially available ferumoxides suspen-
sion (Fe) (Feridex IV; Bayer-Schering Pharma, Wayne, NJ, USA)
was first added to the cells by directly pipetting into the culture dish
to the final concentration of 100 mg/ml. Immediately after,
preservative-free protamine sulfate (Pro) (American Pharmaceuticals
Partners, Shaumburg, IL, USA) was added in the same manner to
the final concentration of 3 mg / m l .P r ow a ss u p p l i e da s1 0m g / m l
of stock solution and was freshly diluted to a concentration of 1 mg/
ml in distilled water at the time of use. Cells were incubated in the
presence of FePro complexes for 15 minutes at 37uC, 5% CO2,
Figure 1. Growth kinetics of CB AC133+ cells. CB AC133+ cells
were cultured in the presence of 40 ng/ml of stem cell factor (SCF),
40 ng/ml of FLT3 and 10 ng/ml of thrombopoietin (TPO) for 30 days.
Cell numbers were determined by Trypan blue exclusion assay at the
time points indicated on the graph. During the ‘lag phase’ (day 0–8)
there was no significant increase in numbers with time. Starting at day 8
the living cell population increased rapidly with time at an exponential
growth in numbers, and the growth rate increasing with time. Increase
in the cell numbers expressed as fold increase (cell numbers at splitting/
cell numbers at day 0). Data points, means 6 SD. * p,0.05.
doi:10.1371/journal.pone.0009173.g001
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the labeling procedure was further continued for 4 h at 37uC, 5%
CO2. Upon labeling, cells were harvested, washed two times with 1x
PBS and 3610
6 cells suspended in 100 mlo f1 xP B Sw e r e
intravenously administered to matrigel implant bearing Balb/c nude
mice. Cell labeling efficiency was determined by Prussian blue
staining and by determining the intracellular iron concentration
according to our published method [23].
Subcutaneous Matrigel Plug
Animal experiments were performed according to the protocol
approved by our animal care and user committee at Henry Ford
Health System. Subcutaneous matrigel plug mouse model was
generated using 6 to 8 weeks old female or male Balb/c nude mice
(Charles River Laboratories, MD). To mimic angiogenic environ-
ment of the ischemic tissue that would attract circulatory EPCs,
300 ml of Matrigel (BD Bioscience) was mixed with SDF-1
chemoatractant (50 ng/ml) and subcutaneously implanted into
the mice flanks. Immediately after implantation mice received
3610
6 of FePro labeled EPCs via I.V. injection after which
angiogenesis within the matrigel was allowed to develop for 7 days.
Mice were euthanized 7 days after matrigel implantation, matrigel
plugs with the surrounding tissues were harvested and analyzed by
ex vivo MRI and immunohistochemistry.
Ex Vivo MR Imaging Protocol
The mice were deeply sedated using CO2 inhalation and
euthanized. Immediately after, animals were perfused through the
left ventricle with PBS followed by 4% paraformaldehyde (PFA)
after which matrigel implants with surrounding tissues were
removed and placed into 4% PFA and 3% sucrose. Ex vivo MRI
was performed using a 3 Tesla clinical MRI (GE Excite) with a
dedicated small animal-imaging coil (Dody scientific, SC). Fixed
tissues were imaged in fomblin perfluoropolyether (Fomblin,
Ausimont USA, Thorofare, NJ). Three-dimensional 200 mm
isotropic 3D FIESTA images were obtained using TR=17.35 ms,
TE=8.58 ms, FA=40, 666 cm FOV, 3006300 matrices,
0.2 mm thick, NEX=2. Multiplanar reconstruction was per-
formed using Voxar 3D software.
Immunohistochemistry and Prussian Blue Staining
After the ex-vivo MR imaging, matrigel plug with surrounding
tissues were prepared for frozen sectioning. Ten micron sections
were cut and stained with FITC conjugated tomato lectin to
visualize the newly formed vasculature while nuclei were visualized
with DAPI. The very adjacent tissue sections were stained with
DAB enhanced Prussian blue to confirm the presence of FePro
labeled administered CB AC133+ cells. Prussian blue staining was
performed according to our previously reported method [24].
Figure 2. Expression of cell surface markers in CB AC133+ progenitor cells during long term in vitro culture. The data depicts the levels
of CD133 and CD34 protein expression in AC133+ cells cultured for 4, 10 and 20 days (A) and the levels of CD31, CD105, CD184, CD29 and CD117 in
AC133+ cells cultured for 10 and 20 days (B). Flow cytometric histograms from one representative experiment are shown (n=3). At least 10,000 live
gated cells were analyzed for FITC, PE or PE-Cy5 expression. Isotype controls are shown as solid blue histograms.
doi:10.1371/journal.pone.0009173.g002
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Each experiment was performed at least two times and each
sample was tested in triplicate. Data are expressed as mean6SD.
Statistically significant difference was determined with one way
ANOVA analysis followed by Fisher’s PLSD post-hoc test, when
there were more than two groups. For analysis between two
groups student-t test was used. A value of p,0.05 was considered
significant.
Results
Growth Potential and Endothelial Progenitor
Characteristics of CB AC133+ Cells during Long Term In
Vitro Culture
Although the majority of previous work on isolation and
characterization of the putative EPC utilized adherent culture
conditions as a mode for in vitro cell propagation, we investigated the
possibility of using suspension culture for CB AC133+ cells long term
expansion. Thus, during the 30-day culture we analyzed the growth
potential of CB AC133+ and the expression of cell surface markers
indicative of endothelial progenitor phenotype. Upon isolation from
cord blood, AC133+ cells were grown in media containing 40 ng/ml
of stem cell factor (SCF), 40 ng/ml of Fms-related tyrosine kinase 3
ligand (Flt3 ligand) and 10 ng/ml of thrombopoietin (TPO). We
started the long-term expansion with 5.8610
5–6.8610
5 cells per
culture. Cells were maintained in culture for 30 days at the
concentration of 5610
5–1610
6 cells/ml and the fold expansion was
determined by periodically counting the numbers of live cells using
t h eT r y p a nb l u ee x c l u s i o na s s a y .A ss h o w ni nF i g u r e1 ,s i g n i f i c a n t
increase in cell numbers was observed after 8 days of cell expansion.
This significant difference in cell numbers, compared to the cell
numbers at day 0, was maintained during 4 weeks of culturing and at
day 27 of culture cells achieved 148 fold expansion (Figure 1). As
markers for immature endothelial progenitors, we examined AC133
and CD34. Upon isolation, majority of cells exhibited the expression
of AC133 and CD 34 (.90%) (data not shown). As expected, at day
4, cells down-regulated the expression of AC133 and CD34 with the
complete loss of AC133 expression by day 10 and CD34 by day 20
of primary culture (Figure 2A). In addition, by day 10 in culture,
cells upregulated the expression of EC surface markers such as
CD31, CD105, CD184 and CD29, and as expected, this increase in
expression was maintained at the later time (day 20) in culture
(Figure 2B). The expression of CD117 (c-kit) marker was still
present on more than 50% of cells at day 10 and on 15% of the cells
at day 20, indicating the presence of actively proliferating
progenitors.
The Effect of Long Term In Vitro Expansion on
Differentiation Potential of CB AC133+ Cells
To characterize the differentiation potential of long term CB
AC133+ culture to give rise to EC type, cells were plated on
fibronectin coated surface in the presence of 2% FBS and 2 ng/ml
of VEGF at days 5–6, 10–15 and 25–30 of primary culture. Cells
were differentiated for 2 weeks and analyzed for the changes in cell
morphology and expression of mature EC specific markers.
During the course of differentiation, similar patterns with regard
Figure 3. Morphological changes in CB AC133+ cells differentiated for 2 weeks. The similar pattern of morphological changes was
observed in cells differentiated at day 15 (A, B) and at day 30 (C, D) of primary culture. Differentiated cells exhibited ‘‘cobble stone’’-like
organizational pattern. Spindle shaped adherent cells sprouted from cell clusters in an attempt to organize into linear, tube-like structures. Phase
contrast photomicrographs from 2 representative experiments. Magnifications used: 10x (A and C) and 25x (B and D). Scale bar =100 mm.
doi:10.1371/journal.pone.0009173.g003
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differentiate at different time points post-isolation. As revealed by
light microscopy, in all the experiments, at about day 10 of
differentiation, majority of cells attached to the surface forming the
areas exhibiting ‘‘cobble stone’’-like organizational pattern, and
spindle-shaped adherent cells sprouted from cell clusters in an
attempt to organize into linear, tube-like structures. The similar
pattern of morphological changes was observed in cells differen-
tiated at day 10–15 (Figure 3A-B) and at day 25–30 (Figure 3C-
D) of primary culture. In addition to the changes in cell
morphology, differentiation process is associated with phenotypical
changes that include changes in expression of specific cell surface
proteins that play important roles in regulating functional
competence of endothelial type cells. Flow cytometric analysis
showed that after 2 weeks of differentiation majority of the cells
were positive for CD31, CD54, CD184, KDR, CD62E, CD 29,
CD150, CD 195 and CD 105 (Figure 4). Certain percentage
(40%) of cells also expressed VE-Cadherin. Fluorescent microsco-
py revealed that the majority of cells exhibited expression of
CD31, VEGFR2 and von Willebrand factor (vWF) when they
were induced to differentiate at day 5–6 (Figure 5A), day 10–15
(Figure 5B) and 25–30 (Figure 5C) of primary culture. The
observed pattern of expression and morphological features
indicates that long term in vitro culturing did not impede CB
AC133+ cells’ potential to differentiate towards ECs.
The Effect of Long Term In Vitro Expansion on Functional
Properties of CB AC133+ Cells
To address the question whether CB AC133+ cells exhibited
functional characteristics of physiologically competent ECs, uptake
of acetylated low-density lipoprotein (Ac-LDL), ability to form
tube like formation and migrate in response to chemoatractants
were tested.
Acetylated – LDL is taken up by ECs via the ‘‘scavenger cell
pathway’’ of LDL metabolism and this metabolism in ECs has
been shown to be at the accelerated rate compared to other cells
types [25,26]. Uptake of Ac-LDL was very often used to identify
EC population [27,28] and to assess ECs’ functional integrity
[29,30]. Therefore we analyzed the uptake of DiI-Ac-LDL in CB
AC133+ cells that were differentiated for two weeks at days 5–6,
Figure 4. Expression of cell surface markers in CB AC133+ progenitor cells differentiated for two weeks. CB AC133+ progenitor cells at
day 31 of primary culture were differentiated for two weeks. Flow cytometric analysis showed that after 2 weeks of differentiation cells were positive
for CD31, CD54, CD184, KDR, CD62E, CD29, CD150, CD195, CD105 and VE Cadherin. Flow cytometric histograms from one representative experiment
are shown (n=3). At least 10,000 live gated cells were analyzed for FITC, PE or PE-Cy5 expression. Isotype controls are shown as solid blue histograms.
doi:10.1371/journal.pone.0009173.g004
Cord Blood AC133+ Cells
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panel), Figure 5B (first panel) and Figure 5C (last panel)
differentiated cells exhibited uptake of DiI-Ac-LDL that was
displayed as uniform, perinuclear red fluorescence. This pattern is
typical of mature ECs and it indicated the presence of functional
ECs population.
The ability of long term expanded CB AC133+ cells to respond
to the extracellular matrix components by forming tubular
structures was analyzed at day 10–15 and 25–30 of primary
culture, by plating the cells on matrigel coated dishes for 24 h.
After 24 h of co-culture with HDMVEC, CB AC133+ cells
exhibited migratory and organizational pattern indicative of
incorporation into the tube like structures. As shown in
Figure 6A-D, HDMVECs labeled with Calcein (green fluores-
cence) and CB AC133+ cells labeled with DiI (red fluorescence)
co-localized to form tube like structure. Most of the green
fluorescent cells appeared to be structural part of the tubes, while
some of the red florescence cells that did not became part of the
tube network remained scattered in between the tubes. It is
plausible that structural basis for the observed tube structure came
from HDMVECs, with CB AC133+ playing a supporting role. To
address that question, we incubated HDMVECs in the presence of
CB AC133+ cells’ supernatants (w/o EPCs and VEGF) for 24 h
after which HDMVECs formed complete tubes in matrigel
(Figure 6E). This data indicated also the possible indirect,
paracrine angiogenic role for CB AC133+ progenitors. When
plated alone, CB AC133+ did not form tube like structures
(Figure 6F).
One of the important characteristics of the cells of endothelial
lineage is the ability to exhibit directional migration, i.e.
chemotaxis, along the concentration gradients of biologically
active, low molecular weight peptides called chemokines. There-
fore we analyzed the effect of long term culturing on CB AC133+
cells’ chemotaxis by determining their ability to migrate along the
concentration gradients of SDF-1a and Rantes chemokines under
the in vitro conditions. In addition to in vitro migration, we tested
CB AC133+ cells’ migratory capacity in vivo, by employing
matrigel plug model in Balb/c nude mice. At days 10–15 and 25–
30 of primary culture, CB AC133+ cells were incubated for 4 h in
the presence of 50 ng/ml of either SDF-1a or Rantes. Cell
migration in response to these two chemokines was significantly
higher (p,0.05) than that observed in control conditions (w/o
Figure 5. Expression of CD31, vWF and KDR in differentiated CB AC133+ progenitors. Cells were induced to differentiate at day 5–6 (A),
day 10–15 (B) and day 25–30 (C) of primary culture. Positive signals were visualized with FITC conjugated secondary antibody (green) and Rho
conjugated secondary antibody (red). Nuclei were visualized with DAPI (blue). CD31 positive (left panels in A and B) and KDR positive (right panel in
C) cells also exhibited the uptake of DiI-Ac-LDL (red). Photomicrographs (40x) of differentiated cells representative of 3 other experiments. Scale bar
=100 mm.
doi:10.1371/journal.pone.0009173.g005
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10–15 and the cells cultured for 25–30 days (Figure 7). In
addition, similar significant increase in migration was observed
when cells were incubated in the presence of 10% FBS, that served
a positive control for migratory response. These data indicate that
during the long term culturing CB AC133+ progenitors
maintained functional characteristics with regard to chemotaxis.
To assess the capacity of CB AC133+ cells to in vivo migrate and
incorporate into the sites of neovascularization we used matrigel
plug model in Balb/c nude mice. After in vitro expansion for 10–15
days, CB AC133+ cells were magnetically labeled with FePro and
administered intravenously into the matrigel implant bearing
Balb/c nude mice. Our extensive previous research on a variety of
cell types showed that FePro labeling does not have significant
effect on cellular physiology [24,31]. Seven days post injection
MRI and immunohistochemistry revealed that FePro labeled CB
AC133+ cells migrated towards neovasculature within the matrigel
implants. This migration was detected by ex vivo MRI as
hypointensity areas resulting from T2* shortening due to the
presence of FePro labeled cells (Figure 8A-B). At the same time
lectin (Figure 8C) and DAPI (Figure 8D) fluorescent, and
Prussian blue (Figure 8E) staining of sections generated from the
areas exhibiting hypointensity MRI signals revealed the co-
localization of labeled cells with newly formed tube structures.
Discussion
The hallmark of EPCs is their ability to proliferate, circulate and
give rise to functional progeny. Due to these properties they have a
huge therapeutic potential with respect to vessel repair and
neovascularization in ischemic diseases, as well as a possible gene
carriers or delivery systems in conditions such as tumors, which are
closely associated with ischemia. However, isolating EPCs is a
challenging task due to their very low in vivo numbers. Previous
reports showed that bone marrow contains less than 0.05% of
EPC while in the peripheral blood only 0.01% of mononuclear
cells are EPCs [13,32]. In recent years, human umbilical cord
blood became an interesting source of various types of stem/
progenitor cells [33,34,35], including hematopoietic [36,37] and
AC133+ stem/progenitor cells. Previous work have shown that the
numbers of EPCs generated from cord blood are higher (up to
0.64%) than the numbers generated from human peripheral blood
[13,38]. In addition, CB AC133+ cells represent a multipotent
adult stem/progenitor cell population that can self-renew and
differentiate to a variety of specialized cells [38,39,40]. Taken
together, currently available data indicate that CB AC133+ cells
may be one of the best candidates for developing therapies for
vascular ischemic diseases. Although the exact numbers needed for
the successful in vivo therapeutic neovascularization are not known,
in vitro cell amplification appears to be a necessary step in gaining
the appropriate quantities of cells needed.
Having the very controversial data on the identity and source of
EPCs in mind, here we ask whether cord blood derived AC133+
progenitors can preserve their endothelial cell type properties
Figure 6. Functional analysis of long term expanded CB
AC133+ cells to form tubes in Matrigel. Tube like structures after
24 h of CB AC133+ cells and HDMVECs co-culture (A-D). Complete
tubes in matrigel formed by HDMVECs incubated in the presence of CB
AC133+ cells’ supernatants (w/o EPCs and VEGF) for 24 h (E). When
plated alone, CB AC133+ did not form tube like structures (F). Note in
panels A-D, HDMVECs labeled with Calcein (C, green fluorescence) and
CB AC133+ cells labeled with DiI (D, red fluorescence) co-localized
(yellow; panel A) to form tube like structure. Most of the green
fluorescent cells appeared to be structural part of the tubes, while some
of the red florescence cells that did not became part of the tube
network remained scattered between the tubes. Overlays of bright light
microscopy and fluorescent microscopy images (A, C, D). Bright light
microscopy only, images shown in panels B, E and F. Magnification 10x.
doi:10.1371/journal.pone.0009173.g006
Figure 7. Effect of long term in vitro expansion on CB AC133+
cell chemotaxis in response to SDF1-a and Rantes. At days 15
and 30 of primary culture, CB AC133+ cells were incubated for 4 h in the
presence of 50 ng/ml of either Rantes or SDF-1a. Cell migration in
response to these to chemokines was significantly higher (p,0.05) than
that observed in control conditions (w/o chemoatractant; gray bars),
with no difference between the cells cultured for 15 and the cells
cultured for 30 days. Cells incubated in the presence of 10% FBS (black
bars) were used as a positive control. Bars, means 6 SD. * p,0.05.
doi:10.1371/journal.pone.0009173.g007
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presence of SCF, Flt3 ligand and TPO isolated AC133+
population maintained endothelial precursors for at least 30 days
of in vitro culture. The phenotypic characteristics of these
precursors were exhibited as down regulation and complete loss
of CD133 and CD34 marker expression early in the culture (day
4–10) and as up-regulation of CD31, CD105, CD184, CD29 and
CD117. The observed down-regulation of CD133 and CD34
molecules with the increased time in culture indicated the presence
of more mature endothelial progenitors. Although this phenom-
enon has been previously reported, the time points when
significant decrease in the percentage of cells expressing CD133
and CD34 was detected ranged from day 7 to day 30 after
isolation of AC133+ cells [38,41,42,43]. The discrepancy in the
observed dynamic of CD133 and CD34 expression, as well as in
CD31, CD105, CD184, CD29 and CD117 expression may reflect
the differences in culture conditions with regard to cytokine
compositions and cell growth surface employed by distinct groups.
Nevertheless, the overall pattern of expression at any time during
the long term culture was indicative of maturation and functional
status of the cultured cells. The expression of proteins such as
PECAM-1 (CD31), endoglin (CD105) and integrin (CD29)
indicated the commitment of these cells towards endothelial
lineage. Although expressed on various other cell types, SDF-1
receptor (CD184, CXCR4) is also typically expressed on
endothelial cells and is important for cellular migration within
the hypoxic environment in ischemic tissues. On the other hand,
at day 10 of the culture significant number of cells still maintained
the expression of SCF receptor c-kit (CD117) and that expression
indicated the presence of actively proliferating precursors.
Although never completely disappearing, the percentage of
CD117 positive cells became less at day 20 of culture. However,
the CB AC133+ exhibited robust proliferative response to the
culture conditions and at the very end of in vitro culture exhibited
148-fold population expansion. It is possible that over the course of
30 day CB AC133+ culture becomes heterogeneous population,
containing highly proliferative, more immature cells and less
immature cells with more pronounced endothelial characteristics.
However, the answer to this question cannot be provided by the
current study and will necessitate analysis at the single cell level,
which is part of our future studies.
One of the pivotal properties of EPCs is the ability to give rise to
the functional progeny, i.e. mature endothelial cells. Considering
that our findings demonstrated that at mid time point in the
culture cell population became heterogeneous, it was critically
important to determine whether ability to differentiate and carry
the function of endothelial cells was affected by long term in vitro
expansion. The main features indicative of acquiring endothelial
phenotype are changes in cellular morphology and expression of
specific mature endothelial markers. Many groups considered the
expression of CD31, VEGF receptor 2 (KDR) and von Willebrand
factor as the expression hallmarks of endothelial cell type. In
addition to these markers, we demonstrated that long term
expanded CB AC133+ cultured under differentiation conditions
also expressed ICAM-1 (CD54), E-selectin (CD62E) and SLAM
(CD150). Cells maintained under the growth (non-differentiating)
conditions also expressed CD105, CD29 and CD184; however,
these molecules were strongly upregulated and expressed on 100%
of cells that were cultured under the differentiating conditions.
The CD105 increase under the differentiating conditions also
correlated to the data gained from the study by Senegaglia et al
[38]. Collectively, these data are in agreement with the expected
changes in cell shape, motility and ability to migrate that are
associated with EC differentiation and at the same time are the
properties necessary to carry out angiogenic effects of mature
endothelial cells. Altogether, we show that under the appropriate
Figure 8. Migration and accumulation of FePro labeled CB AC133+ cells in the matrigel plug detected by MRI and
immunohistochemistry. Isotropic 200 mm ex vivo MRI image obtained in coronal plan by FIESTA sequence (A) and the reconstructed 200 mm
image of the sagital view (B). Administered FePro labeled CB AC133+ cells generated low signal intensity areas seen on both images (arrows in the
circle). Fluorescent DAPI staining of the matrigel section that corresponds the MRI images show multiple cells within the matrigel (C) and the cells are
mostly seen within a tube like structures depicted by FITC labeled tomato lectin (D). DAB-enhanced Prussian blue staining of the section very adjacent
to the section stained with DAPI and FITC-lectin shows multiple, iron-positive, administered cells within the tube like structure (E). Scale bar =100 mm.
doi:10.1371/journal.pone.0009173.g008
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cells with endothelial characteristics with no difference between
the cells expanded for 10–15 days and the one expanded for 20–25
days.
Functional testing using matrigel tube formation assay
showed that CB AC133+ failed to form cord like structures
when plated alone. The observed results contrasted the previous
reports on CB AC133+ cells [38] that indicated self-sufficiency
of these cells for generating tube like structures. However, our
results from CB AC133+ cells – HDMVECs co-culture matrigel
experiments showed that CB AC133+ cells migrated and co-
localized with the HDMVECs that formed tube like structures.
In addition, HDMVECs incubated in the presence of EPCs’
supernatants (w/o EPCs) formed complete tubes in matrigel.
Diversity of CB AC133+ cells’ growth culture conditions used
by various groups may explain the contrary results reported in
the literature that concerns particular aspects of progenitor
function and it is possible that certain growth factors would
promote or inhibit some of the functional properties. In
particular, growth conditions used by most of the researchers
that promoted cell attachment in the presence of FBS may have
influenced the formation of more mature cells that were able to
make tubes by themselves. On the other hand, our data indicate
that EPCs may exert their proangiogenic effect in a paracrine
fashion, as previously indicated by findings showing that under
ischemic conditions EPC may induce neovascularization
by secreting growth factors andc y t o k i n e s( s u c ha sV E G F )t h a t
induce sprouting angiogenesis by the neighboring endothe-
lium [44].
One of the hallmarks of tissue ischemia is increase in the SDF-1
expression, generating strong migratory signal for circulating
EPCs [45,46]. In addition to responsiveness to ischemic stimuli,
functional EPCs are characterized by the ability to respond to
inflammatory stimuli (such as RANTES) as well. The capacity to
migrate in response to the such stimuli is crucial for endothelial
progenitors to exert their angiogenic potential and participate in
neovascularization processes and the importance of this chemo-
taxis was demonstrated by many groups [47,48,49]. Here we also
showed that that during the long term culturing, CB AC133+
progenitors maintained functional characteristics with regard to
chemotaxis and exhibited similar migratory response to SDF-1a
and RANTES at day 10–15 and at day 25–30 of culture. In
addition, we demonstrated that long term in vitro expansion did not
impede the ability to migrate and incorporate into neovascular-
ization sites under in vivo conditions. Our previous studies on
tumor animal models also showed that locally [50] and
systemically [51] administered FePro labeled CB AC133+ cells
migrated and incorporated into the tumor vasculatures.
In summary, our results indicate that long term culturing can
give significant quantities of CB AC133+ cells that preserved the
capacity to differentiate into functional mature ECs and can be
used in the studies relevant to the development of future
angiogenic therapies as well as in studies on progenitor cell
biology and development.
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